KR101733247B1 - 외상 후 스트레스 장애를 치료하기 위한 테트라하이드로퀴놀린 유도체 - Google Patents

외상 후 스트레스 장애를 치료하기 위한 테트라하이드로퀴놀린 유도체 Download PDF

Info

Publication number
KR101733247B1
KR101733247B1 KR1020107010186A KR20107010186A KR101733247B1 KR 101733247 B1 KR101733247 B1 KR 101733247B1 KR 1020107010186 A KR1020107010186 A KR 1020107010186A KR 20107010186 A KR20107010186 A KR 20107010186A KR 101733247 B1 KR101733247 B1 KR 101733247B1
Authority
KR
South Korea
Prior art keywords
phenyl
compound
formula
alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107010186A
Other languages
English (en)
Korean (ko)
Other versions
KR20100065203A (ko
Inventor
프랑수아 젠크
Original Assignee
액테리온 파마슈티칼 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40467356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101733247(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 액테리온 파마슈티칼 리미티드 filed Critical 액테리온 파마슈티칼 리미티드
Publication of KR20100065203A publication Critical patent/KR20100065203A/ko
Application granted granted Critical
Publication of KR101733247B1 publication Critical patent/KR101733247B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020107010186A 2007-10-10 2008-10-09 외상 후 스트레스 장애를 치료하기 위한 테트라하이드로퀴놀린 유도체 Expired - Fee Related KR101733247B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
WOPCT/IB2007/054130 2007-10-10
IB2007054130 2007-10-10
PCT/IB2008/054138 WO2009047723A2 (en) 2007-10-10 2008-10-09 Tetrahydroquinoline derivatives for treating post-traumatic stress disorders

Publications (2)

Publication Number Publication Date
KR20100065203A KR20100065203A (ko) 2010-06-15
KR101733247B1 true KR101733247B1 (ko) 2017-05-08

Family

ID=40467356

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107010186A Expired - Fee Related KR101733247B1 (ko) 2007-10-10 2008-10-09 외상 후 스트레스 장애를 치료하기 위한 테트라하이드로퀴놀린 유도체

Country Status (27)

Country Link
US (1) US9532985B2 (enExample)
EP (1) EP2207550B1 (enExample)
JP (1) JP5883222B2 (enExample)
KR (1) KR101733247B1 (enExample)
CN (1) CN101820878B (enExample)
AR (1) AR068768A1 (enExample)
AU (1) AU2008309194B2 (enExample)
BR (1) BRPI0818617A2 (enExample)
CA (1) CA2699504C (enExample)
CY (1) CY1114799T1 (enExample)
DK (1) DK2207550T3 (enExample)
EA (1) EA017443B1 (enExample)
ES (1) ES2444418T3 (enExample)
HR (1) HRP20140214T1 (enExample)
IL (1) IL204838A (enExample)
MA (1) MA31800B1 (enExample)
MX (1) MX2010003711A (enExample)
MY (1) MY153044A (enExample)
NZ (1) NZ585086A (enExample)
PE (1) PE20091010A1 (enExample)
PL (1) PL2207550T3 (enExample)
PT (1) PT2207550E (enExample)
SI (1) SI2207550T1 (enExample)
TW (1) TWI428129B (enExample)
UA (1) UA99150C2 (enExample)
WO (1) WO2009047723A2 (enExample)
ZA (1) ZA201003251B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2669561A1 (en) 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
KR20110036069A (ko) 2008-06-25 2011-04-06 액테리온 파마슈티칼 리미티드 5,6,7,8-테트라히드로-이미다조[1,5-ａ]피라진 화합물
EP2402322A1 (en) 2010-07-02 2012-01-04 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist
KR101802726B1 (ko) 2010-08-24 2017-11-29 액테리온 파마슈티칼 리미티드 오렉신 수용체 안타고니스트로서의 프롤린 술폰아미드 유도체
MY160969A (en) 2010-09-22 2017-03-31 Eisai R&D Man Co Ltd Cyclopropane compounds
CA2815179A1 (en) 2010-11-10 2012-05-18 Actelion Pharmaceuticals Ltd Lactam derivatives useful as orexin receptor antagonists
WO2012085857A1 (en) 2010-12-22 2012-06-28 Actelion Pharmaceuticals Ltd 3,8-diaza-bicyclo[4.2.0]oct-3-yl amides
CN103380130B (zh) 2011-02-18 2015-06-17 埃科特莱茵药品有限公司 用作为食欲素拮抗剂的新颖的吡唑和咪唑衍生物
WO2012114252A1 (en) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
WO2013050938A1 (en) 2011-10-04 2013-04-11 Actelion Pharmaceuticals Ltd 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives
EA024106B1 (ru) 2011-11-08 2016-08-31 Актелион Фармасьютиклз Лтд. Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида
PT2855453T (pt) 2012-06-04 2017-03-09 Actelion Pharmaceuticals Ltd Derivados de benzimidazol-prolina
WO2014057435A1 (en) 2012-10-10 2014-04-17 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
EP2970241A1 (en) 2013-03-12 2016-01-20 Actelion Pharmaceuticals Ltd. Azetidine amide derivatives as orexin receptor antagonists
PL3077389T3 (pl) 2013-12-03 2018-03-30 Idorsia Pharmaceuticals Ltd KRYSTALICZNA POSTAĆ (S)-(2-(6-CHLORO-7-METYLO-1H-BENZO[D]lMIDAZOL-2-ILO)- 2-METYLOPIROLIDYN-1-YLO)(5-METOKSY-2-(2H-1,2,3-TRIAZOL-2-ILO)FENYLO)METANONU I JEJ ZASTOSOWANIE JAKO ANTAGONISTY RECEPTORA OREKSYNY
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
UA116053C2 (uk) 2013-12-04 2018-01-25 Ідорсія Фармасьютікалз Лтд Застосування похідних бензоімідазолу-проліну
MX376164B (es) 2014-10-23 2025-03-07 Eisai R&D Man Co Ltd Composiciones y metodos para tratar el insomnio.
WO2019024845A1 (zh) * 2017-08-01 2019-02-07 苏州科睿思制药有限公司 一种食欲素受体拮抗剂的晶型及其制备方法和用途
WO2020007964A1 (en) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
WO2020007977A1 (en) 2018-07-06 2020-01-09 Idorsia Pharmaceuticals Ltd 7-trifluoromethyl-[1,4]diazepan derivatives
WO2020099511A1 (en) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
TW202400149A (zh) 2022-05-13 2024-01-01 瑞士商愛杜西亞製藥有限公司 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001260113B2 (en) * 2000-03-14 2006-04-06 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivatives
KR20050114242A (ko) 2003-03-26 2005-12-05 액테리온 파마슈티칼 리미티드 오렉신 수용체 길항제로서 이용되는테트라하이드로이소퀴놀릴 아세트아마이드 유도체
US7763638B2 (en) * 2004-03-01 2010-07-27 Actelion Pharmaceuticals Ltd. Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
US7501395B2 (en) * 2005-04-25 2009-03-10 Eisai R & D Management Co., Ltd. Method of screening for antianxiety drugs
CA2644010A1 (en) * 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Tetrahydroisoquinoline derivatives to enhance memory function
EP2402322A1 (en) 2010-07-02 2012-01-04 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J Clin Psychiatry, Vol.60, No.16 (1999)*

Also Published As

Publication number Publication date
HK1145440A1 (en) 2011-04-21
IL204838A0 (en) 2010-11-30
EP2207550B1 (en) 2013-12-11
JP2011500550A (ja) 2011-01-06
CA2699504C (en) 2015-11-24
EA201000557A1 (ru) 2010-10-29
NZ585086A (en) 2012-03-30
BRPI0818617A2 (pt) 2015-04-07
PT2207550E (pt) 2014-02-07
EA017443B1 (ru) 2012-12-28
WO2009047723A2 (en) 2009-04-16
AU2008309194B2 (en) 2013-10-03
MA31800B1 (fr) 2010-10-01
ES2444418T3 (es) 2014-02-25
TW200932231A (en) 2009-08-01
DK2207550T3 (da) 2014-01-27
UA99150C2 (ru) 2012-07-25
CN101820878A (zh) 2010-09-01
MY153044A (en) 2014-12-31
CA2699504A1 (en) 2009-04-16
WO2009047723A3 (en) 2009-05-28
PL2207550T3 (pl) 2014-05-30
SI2207550T1 (sl) 2014-03-31
IL204838A (en) 2014-09-30
CN101820878B (zh) 2012-02-01
HRP20140214T1 (hr) 2014-04-11
AU2008309194A1 (en) 2009-04-16
US9532985B2 (en) 2017-01-03
TWI428129B (zh) 2014-03-01
PE20091010A1 (es) 2009-08-08
CY1114799T1 (el) 2016-12-14
ZA201003251B (en) 2011-07-27
EP2207550A2 (en) 2010-07-21
JP5883222B2 (ja) 2016-03-09
US20100234420A1 (en) 2010-09-16
KR20100065203A (ko) 2010-06-15
MX2010003711A (es) 2010-04-30
AR068768A1 (es) 2009-12-02

Similar Documents

Publication Publication Date Title
KR101733247B1 (ko) 외상 후 스트레스 장애를 치료하기 위한 테트라하이드로퀴놀린 유도체
JP2010531810A (ja) 点眼投与による神経疾患または精神神経疾患の治療または予防
US20060003985A1 (en) Enhancement of sleep with t-type calcium channel antagonists
JP2009525979A (ja) ４−アシルアミノピリジン誘導体を介した神経新生
SK287180B6 (sk) Kombinácia účinných látok na medikamentóznu terapiu návykových alebo omamných prostriedkov
JP2008542417A (ja) 進行性ミオクローヌスてんかんに特徴付けられる疾患の治療用ブリバラセタムの使用
Deshmukh et al. Review on analgesic activity and determination methods
KR101146807B1 (ko) 각성을 향상시키는 방법
US20070032553A1 (en) Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
KR20010072184A (ko) 난치성 간질 치료약 또는 예방약
Corletto et al. Pharmacological treatment of pain
HK1145440B (en) Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
CN114159568B (zh) Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
CN101321524A (zh) 雌激素β激动剂的新用途
WO1995006468A1 (en) Method for treating migraine headaches
WO2025102989A1 (zh) 靶向O-GlcNAc糖苷水解酶抑制剂促进髓鞘再生
CN107648235B (zh) 普纳替尼在制备治疗缺血/再灌注损伤药物中的应用
JP2025502526A (ja) てんかんにおける突然の予期せぬ死に関連する疾患を治療するためのセロトニン５－ｈｔ１ａ受容体アゴニストの使用
CN117715638A (zh) 治疗或预防与阿片类物质戒断或阿片类物质复发相关的病症的方法
JP2023539391A (ja) セスキテルペンラクトン系化合物の視神経炎治療薬の製造における使用
CN101242836A (zh) 改善觉醒状态的方法
HK40009658A (zh) 治疗瘙痒和/或搔痒的方法
TW200524920A (en) Treatment of circadian rhythm disorders with NPY Y5 receptor antagonist

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

J301 Trial decision

Free format text: TRIAL NUMBER: 2015101004801; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20150819

Effective date: 20170222

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20170222

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2010 7010186

Appeal request date: 20150819

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015101004801

PS0901 Examination by remand of revocation

St.27 status event code: A-6-3-E10-E12-rex-PS0901

S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

St.27 status event code: A-3-4-F10-F13-rex-PS0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240428

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240428